Michael Albert MD’s Post

It is fun to just take a moment and reflect upon the weight loss we are seeing with all the new medications. Never thought this would happen in our life time after qysmia, contrave and others stalled out. It is sad the access/price remains an issue but clinically, who could have ever predicted this new wave of effective options coming on so incredibly fast.

Very amazing results! I’m curious what they suggested for nutrition, specifically protein intake daily as well as I’m also interested to see if they actually measure your body composition. Something I’m noticing with these trials is you know bodyweight are only 230 pounds. I am curious if we took a subset of patients with higher BMIs is their rate of weight loss higher? I am propsing a study right looking at this topic. Looking at different subsets of BMI cut offs with protien dosing.

What an embarrassment of riches that these results sent their stock tumbling. The pipeline of innovation in this space over the next five years is breathtaking.

https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-next-gen-obesity-drug-cagrisema-achieves-lower-weight-loss-than-2024-12-20/ Below par performance of the product in trial wipes off 125 billion USD off Novo’s market cap. Comparability data with TZP is awaited but early indicators have dwindled investor confidence.

Looking forward to reading the full paper once its published. There seem to be a lot of fine details based on this press release. The flexible dosing will be interesting. I look forward to a time when we have flexible dosing on each component of these combination therapies.